Check out Kristin Yarema & BioCentury on “Creating CAR T therapies that don’t cause cancer"


Mark J. Gergen, Executive Chairman

Executive Chairman

Mr. Gergen transitioned to the role of Executive Chairman of the Poseida board of directors in January 2024, after most recently serving as Chairman and CEO of Poseida and holding a variety of executive roles at Poseida over the previous six years. Mr. Gergen was appointed Chief Executive Officer of Poseida in February 2022 and named Chairman of the Board of Directors in February 2023. He joined Poseida in February 2018, initially serving as Chief Business Officer and Chief Financial Officer before being named President and Chief Business Officer in July 2020. He has been a member of our Board of Directors since 2018. Mr. Gergen was previously the Senior Vice President and Chief Operating Officer of Halozyme, Inc. and Executive Vice President and Chief Operating Officer at Mirati Therapeutics, Inc. Previously he served in senior management positions, including as Senior Vice President of Corporate Development, at Amylin Pharmaceuticals, Inc. He also served in senior management positions at CardioNet Inc., Advanced Tissue Sciences, Inc., and Medtronic, Inc. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University.